KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Current Deferred Revenue: 2013-2020

Historic Current Deferred Revenue for Xenon Pharmaceuticals (XENE) over the last 5 years, with Dec 2020 value amounting to $3.6 million.

  • Xenon Pharmaceuticals' Current Deferred Revenue fell 70.43% to $2.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was $2.2 million, marking a year-over-year decrease of 70.43%. This contributed to the annual value of $3.6 million for FY2020, which is 87.76% down from last year.
  • According to the latest figures from FY2020, Xenon Pharmaceuticals' Current Deferred Revenue is $3.6 million, which was down 87.76% from $29.7 million recorded in FY2019.
  • In the past 5 years, Xenon Pharmaceuticals' Current Deferred Revenue ranged from a high of $29.7 million in FY2019 and a low of $3.6 million during FY2020.
  • Moreover, its 2-year median value for Current Deferred Revenue was $16.7 million (2019), whereas its average is $16.7 million.
  • Data for Xenon Pharmaceuticals' Current Deferred Revenue shows a maximum YoY slumped of 87.76% (in 2020) over the last 5 years.
  • Yearly analysis of 2 years shows Xenon Pharmaceuticals' Current Deferred Revenue stood at $29.7 million in 2019, then slumped by 87.76% to $3.6 million in 2020.